Portfolios - Investment - Medical and health professional investment - Shenzhen Efung Investment Management Co. Ltd.

2018 - 08 - 20

Chipscreen Biosciences

Epidaza (Chidamide) is the first marketed innovative drug developed by a Chinese pharmaceutical company. As an oral HDAC inhibitor, Epidaza targets recurrent peripheral T cell lymphoma. Meanwhile, it can also treat other hematological cancer, solid tumor and even HIV combined with other drugs. Multiple clinical trials are conducted in the U.S., Japan, China and Taiwan.

查看详情

more

2018 - 08 - 20

Ascentage Pharma

Ascentage is a globally-focused, clinical-stage biopharma developing novel therapies for cancers, hepatitis B & age-related diseases. Its expertise is in developing inhibitors of protein-protein interactions (PPIs) to restore apoptosisor programmed cell death. There are seven drug candidates in Phase I or II clinical trials in the U.S., Australia and China, including a novel Bcl-2/Bcl-xL inhibitor as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs).

查看详情

more

2018 - 08 - 20

Frontier Biotech

Frontier Biotech is a research-based, clinical stage pharmaceutical company founded in 2002. The management team have extensive business and development experiences in the US and China pharma/biotech industry. Frontier Biotech leverages China's large patient population, and rapid growing economy and pharmaceutical market, develops innovative pharmaceutical products with worldwide IP protection. Frontier Biotech develops Albuvirtide, the first long-acting anti-HIV drug worldwide, which has been approved by CFDA and launched in the third quarter of 2018. The company is dedicated in the discovery, development and commercialization of innovative therapeutic products for unmet medical needs and under-served patients.

查看详情

more

2018 - 08 - 20

Lifotronic

Established in 2008, Lifotronic is a professional international medical enterprise dedicated to developing better products and services with outstanding value for people’s health and life, fostering a culture of dedication, professionalism, integrity and innovation. As a professional medical device manufacturer, Lifotronic specializes in the development, manufacturing and marketing of Bedside Treatment and Diagnostic products.

查看详情

more

2021 - 08 - 26

Harbour BioMed

Harbour BioMed is a global, clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in the areas of oncology and immunological diseases to address unmet patient’s needs.

查看详情

more

2021 - 08 - 26

OBiO Technology

OBiO Technology (Shanghai) Corp., Ltd. is a biopharmaceutical CDMO/CMO company founded in 2013 which currently has more than 380 employees, over a quarter of whom are educated to PhD and M.Sc level. In 2016, OBiO built its gene therapy manufacturing platform meeting regulatory requirements in China, Europe and the United States. The GMP platform offers holistic CDMO services across plasmid, adeno-associated virus, lentivirus, adenovirus, oncolytic viruses, and cell therapy products for scientists, research facilities, medical institutions, and pharmaceutical companies.

查看详情

more

2021 - 08 - 26

3D Medicines

3D Medicines Inc. is a commercialization stage bio-pharmaceutical company, focused on the field of cancer treatment. With a mission to help people with cancer live longer and better, we commit to developing a new generation of therapies for cancer patients around the world, following a future when cancer is managed as a chronic disease

查看详情

more

2018 - 08 - 21

Apexigen

Apexigen is a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. The company's pipeline of immuno-oncology therapeutic candidates is led by the APX005M program, which is currently in clinical development.Apexigen'sAPXiMAB™ technology platform enables Apexigen and its partners to discover high-quality antibody drug candidates against challenging disease targets. Apexigen has established eight corporate partnerships: five of these partners are conducting clinical trials of antibodies discovered using the APXiMAB™ platform.

查看详情

more

2018 - 08 - 21

Centrexion Therapeutics

Centrexion Therapeutics is transforming the treatment of chronic pain by advancing one of the largest, exclusively pain-focused clinical pipelines of novel, non-opioid therapies. It aims to bridge the safety and efficacy gaps in current approaches to chronic pain management.The pipeline represents the mission to tackle the problem of chronic pain head on by developing treatments that act at new or emerging pharmacological targets and delivering them in ways that best address the particular type of chronic pain. This includes a topical gel, a joint or deeper tissue injection, a spinal delivery, and three separate oral treatments.

查看详情

more

2018 - 08 - 21

Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of novel, differentiated therapies for infectious diseases. Complementing the product pipeline is a disruptive platform technology to discover rare, potent human monoclonal antibodies from patients. Its scientists and leadership team have a proven track record of innovation and successful drug development stewardship of therapeutic candidates from early discovery to commercial implementation.Aridis has been listed on Nasdaq in August 2018.

查看详情

more

2018 - 08 - 21

Resverlogix

Resverlogix is a late-stage clinical biotechnology company dedicated to improving and saving the lives of patients with high-risk cardiovascular disease, diabetes mellitus, and chronic kidney disease.Resverlogix is developing an advanced epigenetic drug called apabetalone for the treatment of high-risk cardiovascular disease patients who also have type 2 diabetes mellitus and low high-density lipoprotein (HDL). The current standard of care for these patients is administration of statins, of which, the two most common are Lipitor and Crestor. Despite maximized use, statins only manage approximately 30 percent of cardiovascular events. The opportunity for apabetalone is in addressing the huge remaining unmet medical need that can be attributed to other unmanaged risk factors such as inflammation. When used in combination with current treatments, apabetalone could address the 70 percent of unmet need in this patient group, specifically the residual inflammatory risk.

查看详情

more